IMFINZI (durvalumab) approved in the US for extensive-stage small cell lung cancer

This article was originally published here

The approval by the US Food and Drug Administration was based on positive results from the Phase III CASPIAN trial showing IMFINZI in combination with SoC platinum-etoposide demonstrated a

The post IMFINZI (durvalumab) approved in the US for extensive-stage small cell lung cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply